{"id":58068,"date":"2023-09-18T19:02:46","date_gmt":"2023-09-18T17:02:46","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/benefits-of-multi-omic-spectral-analysis-in-early-detection-of-multiple-cancers-dxcover-study-published-in-the-british-journal-of-cancer\/"},"modified":"2023-09-18T19:02:46","modified_gmt":"2023-09-18T17:02:46","slug":"benefits-of-multi-omic-spectral-analysis-in-early-detection-of-multiple-cancers-dxcover-study-published-in-the-british-journal-of-cancer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/benefits-of-multi-omic-spectral-analysis-in-early-detection-of-multiple-cancers-dxcover-study-published-in-the-british-journal-of-cancer\/","title":{"rendered":"Benefits of Multi-Omic Spectral Analysis in Early Detection of Multiple Cancers Dxcover Study Published in the British Journal of Cancer"},"content":{"rendered":"
\n

\nHighlights the significant potential of the Dxcover Platform for early detection of cancer<\/i><\/p>\n

GLASGOW, Scotland–(BUSINESS WIRE)–Dxcover Limited<\/a>, a clinical-stage liquid biopsy company pioneering Multi-Omic Spectral Analysis for early detection of cancer, today announced that findings from a large-scale study focused on detection of early stage tumors across multiple cancers has been published in the British Journal of Cancer<\/a>.<\/p>\n

\nIn the study, which recruited 2,092 patients, the Dxcover Platform differentiated cancer against non-cancer patients using Fourier Transform Infrared (FTIR) spectroscopy to analyze all macromolecules in patient serum and combined machine learning algorithms to build spectral profiles that detect breast, colorectal, kidney, lung, ovarian, pancreatic, and prostate cancer. The cancer versus asymptomatic non-cancer classification detected 64% of stage I cancers when specificity was 99%, with an overall sensitivity of 56%. When tuned for higher sensitivity, this model identified 99% of stage I cancers with a specificity of 58%.<\/p>\n

\nWhen examining cancer against all non-cancer (including symptomatic patients), the sensitivity-tuned model enabled 90% sensitivity with 61% specificity, with detection rates of 93% for stage I, 84% for stage II, 92% for stage III and 95% for stage IV.<\/p>\n

\n\u201cThis publication further underscores that Dxcover\u2019s Multi-Omic Spectral Analysis brings significant new data in the fight to detect cancer at the earliest stage when there is the greatest opportunity to save lives. Not only that, but the simplicity of our platform means it can be deployed centrally or locally for reduced cost triage and screening applications. This is a significant step forward in our mission to democratize access to care and deliver treatment to those who need it most,\u201d said Prof. Matthew Baker, co-founder, and Chief Technology Officer at Dxcover.<\/p>\n

\nEarly symptoms of many cancers can be non-specific and easily overlooked by patients and doctors. Delayed diagnosis can permit cancer metastasis and lead to poorer prognosis and increased treatment costs as therapies are typically less effective for late-stage disease. An early detection platform that is capable of detecting multiple cancer types and the precursors of cancer could rule out non-cancer patients and help prioritize at-risk patients for rapid diagnostic investigation. Dxcover has also completed a retrospective colorectal study indicating enhanced capability to detect advanced adenomas, the precursor of colorectal cancer, and will be starting a major prospective collection of samples later this year.<\/p>\n

\nAbout Dxcover Limited<\/b><\/p>\n

\nDxcover is a clinical stage liquid biopsy company developing tests for the early detection of multiple cancers, when treatment has a better chance to impact outcomes. The company has pioneered Multi-Omic Spectral Analysis for the early detection of cancer by infrared spectroscopy and has generated compelling clinical data with high accuracy detection of Stage I and II cancers and adenomas.
\n
Dxcover is based in Scotland, United Kingdom and is expanding its network in Europe and the USA.
\n
For further information go to https:\/\/www.dxcover.com\/science<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia<\/b>
Tara Mulloy
\n
MacDougall Advisors<\/a>
tmulloy@macdougall.bio<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Highlights the significant potential of the Dxcover Platform for early detection of cancer GLASGOW, Scotland–(BUSINESS WIRE)–Dxcover Limited, a clinical-stage liquid biopsy company pioneering Multi-Omic Spectral Analysis for early detection of cancer, today announced that findings from a large-scale study focused on detection of early stage tumors across multiple cancers has been published in the British … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-58068","6":"format-standard","7":"category-industry"},"yoast_head":"\nBenefits of Multi-Omic Spectral Analysis in Early Detection of Multiple Cancers Dxcover Study Published in the British Journal of Cancer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/benefits-of-multi-omic-spectral-analysis-in-early-detection-of-multiple-cancers-dxcover-study-published-in-the-british-journal-of-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Benefits of Multi-Omic Spectral Analysis in Early Detection of Multiple Cancers Dxcover Study Published in the British Journal of Cancer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Highlights the significant potential of the Dxcover Platform for early detection of cancer GLASGOW, Scotland–(BUSINESS WIRE)–Dxcover Limited, a clinical-stage liquid biopsy company pioneering Multi-Omic Spectral Analysis for early detection of cancer, today announced that findings from a large-scale study focused on detection of early stage tumors across multiple cancers has been published in the British ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/benefits-of-multi-omic-spectral-analysis-in-early-detection-of-multiple-cancers-dxcover-study-published-in-the-british-journal-of-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-18T17:02:46+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benefits-of-multi-omic-spectral-analysis-in-early-detection-of-multiple-cancers-dxcover-study-published-in-the-british-journal-of-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benefits-of-multi-omic-spectral-analysis-in-early-detection-of-multiple-cancers-dxcover-study-published-in-the-british-journal-of-cancer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Benefits of Multi-Omic Spectral Analysis in Early Detection of Multiple Cancers Dxcover Study Published in the British Journal of Cancer\",\"datePublished\":\"2023-09-18T17:02:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benefits-of-multi-omic-spectral-analysis-in-early-detection-of-multiple-cancers-dxcover-study-published-in-the-british-journal-of-cancer\\\/\"},\"wordCount\":488,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benefits-of-multi-omic-spectral-analysis-in-early-detection-of-multiple-cancers-dxcover-study-published-in-the-british-journal-of-cancer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benefits-of-multi-omic-spectral-analysis-in-early-detection-of-multiple-cancers-dxcover-study-published-in-the-british-journal-of-cancer\\\/\",\"name\":\"Benefits of Multi-Omic Spectral Analysis in Early Detection of Multiple Cancers Dxcover Study Published in the British Journal of Cancer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2023-09-18T17:02:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benefits-of-multi-omic-spectral-analysis-in-early-detection-of-multiple-cancers-dxcover-study-published-in-the-british-journal-of-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benefits-of-multi-omic-spectral-analysis-in-early-detection-of-multiple-cancers-dxcover-study-published-in-the-british-journal-of-cancer\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benefits-of-multi-omic-spectral-analysis-in-early-detection-of-multiple-cancers-dxcover-study-published-in-the-british-journal-of-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Benefits of Multi-Omic Spectral Analysis in Early Detection of Multiple Cancers Dxcover Study Published in the British Journal of Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Benefits of Multi-Omic Spectral Analysis in Early Detection of Multiple Cancers Dxcover Study Published in the British Journal of Cancer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/benefits-of-multi-omic-spectral-analysis-in-early-detection-of-multiple-cancers-dxcover-study-published-in-the-british-journal-of-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Benefits of Multi-Omic Spectral Analysis in Early Detection of Multiple Cancers Dxcover Study Published in the British Journal of Cancer - Pharma Trend","og_description":"Highlights the significant potential of the Dxcover Platform for early detection of cancer GLASGOW, Scotland–(BUSINESS WIRE)–Dxcover Limited, a clinical-stage liquid biopsy company pioneering Multi-Omic Spectral Analysis for early detection of cancer, today announced that findings from a large-scale study focused on detection of early stage tumors across multiple cancers has been published in the British ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/benefits-of-multi-omic-spectral-analysis-in-early-detection-of-multiple-cancers-dxcover-study-published-in-the-british-journal-of-cancer\/","og_site_name":"Pharma Trend","article_published_time":"2023-09-18T17:02:46+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/benefits-of-multi-omic-spectral-analysis-in-early-detection-of-multiple-cancers-dxcover-study-published-in-the-british-journal-of-cancer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/benefits-of-multi-omic-spectral-analysis-in-early-detection-of-multiple-cancers-dxcover-study-published-in-the-british-journal-of-cancer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Benefits of Multi-Omic Spectral Analysis in Early Detection of Multiple Cancers Dxcover Study Published in the British Journal of Cancer","datePublished":"2023-09-18T17:02:46+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/benefits-of-multi-omic-spectral-analysis-in-early-detection-of-multiple-cancers-dxcover-study-published-in-the-british-journal-of-cancer\/"},"wordCount":488,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/benefits-of-multi-omic-spectral-analysis-in-early-detection-of-multiple-cancers-dxcover-study-published-in-the-british-journal-of-cancer\/","url":"https:\/\/pharma-trend.com\/en\/benefits-of-multi-omic-spectral-analysis-in-early-detection-of-multiple-cancers-dxcover-study-published-in-the-british-journal-of-cancer\/","name":"Benefits of Multi-Omic Spectral Analysis in Early Detection of Multiple Cancers Dxcover Study Published in the British Journal of Cancer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2023-09-18T17:02:46+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/benefits-of-multi-omic-spectral-analysis-in-early-detection-of-multiple-cancers-dxcover-study-published-in-the-british-journal-of-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/benefits-of-multi-omic-spectral-analysis-in-early-detection-of-multiple-cancers-dxcover-study-published-in-the-british-journal-of-cancer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/benefits-of-multi-omic-spectral-analysis-in-early-detection-of-multiple-cancers-dxcover-study-published-in-the-british-journal-of-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Benefits of Multi-Omic Spectral Analysis in Early Detection of Multiple Cancers Dxcover Study Published in the British Journal of Cancer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/58068","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=58068"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/58068\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=58068"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=58068"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=58068"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}